Stockwatch: Cardinal rule adherence – HALO slips but Shire shines
This article was originally published in Scrip
A cardinal rule in pharmaceutical drug development is that you never put the sales of an existing product at risk for a second generation product that may never exist. This is because you don't have to do much risk-adjustment for the sales of a product already on the market - it is real cash flow. However, because there are so many unknowns with a product early in development, you should significantly risk-adjust those cash flows, and not sacrifice the real ones, for the possible ones. Sure, you might get cannibalisation with both first and second generation products end up on the market, but that should be the only harm that one product does to another.
You may also be interested in...
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?
Debt-fueled acquisitions helped Teva, Shire and Allergan report well-received fourth-quarter earnings. But sector circumstances have changed since 2016 and the ability to grow by debt-funded acquisition is now severely restricted.